UBS Group’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $10.5M | Sell |
75,500
-262,800
| -78% | -$36.8M | ﹤0.01% | 3270 |
|
|
2025
Q4 | $41.5M | Sell |
338,300
-35,000
| -9% | -$4.25M | 0.01% | 1818 |
|
|
2025
Q3 | $41.4M | Buy |
373,300
+5,700
| +2% | +$648K | 0.01% | 1823 |
|
|
2025
Q2 | $40.8M | Sell |
367,600
-195,700
| -35% | -$20.8M | 0.01% | 1705 |
|
|
2025
Q1 | $63.1M | Sell |
563,300
-459,700
| -45% | -$47.4M | 0.01% | 1272 |
|
|
2024
Q4 | $94.5M | Buy |
1,023,000
+325,000
| +47% | +$29.3M | 0.02% | 962 |
|
|
2024
Q3 | $58.5M | Buy |
698,000
+166,300
| +31% | +$12.7M | 0.01% | 1051 |
|
|
2024
Q2 | $36.5M | Sell |
531,700
-88,800
| -14% | -$5.93M | 0.01% | 1246 |
|
|
2024
Q1 | $45.5M | Sell |
620,500
-678,600
| -52% | -$52.2M | 0.01% | 1096 |
|
|
2023
Q4 | $105M | Buy |
1,299,100
+32,000
| +3% | +$2.49M | 0.03% | 552 |
|
|
2023
Q3 | $95M | Buy |
1,267,100
+209,800
| +20% | +$16.1M | 0.03% | 520 |
|
|
2023
Q2 | $81.5M | Sell |
1,057,300
-332,200
| -24% | -$26.5M | 0.03% | 580 |
|
|
2023
Q1 | $115M | Sell |
1,389,500
-529,845
| -28% | -$43.9M | 0.04% | 409 |
|
|
2022
Q4 | $165M | Buy |
1,919,345
+810,145
| +73% | +$64.2M | 0.06% | 327 |
|
|
2022
Q3 | $68.4M | Buy |
1,109,200
+223,400
| +25% | +$14.1M | 0.03% | 561 |
|
|
2022
Q2 | $54.8M | Sell |
885,800
-529,100
| -37% | -$32.8M | 0.02% | 683 |
|
|
2022
Q1 | $84.1M | Sell |
1,414,900
-502,200
| -26% | -$32.1M | 0.03% | 577 |
|
|
2021
Q4 | $139M | Buy |
1,917,100
+381,481
| +25% | +$26.3M | 0.04% | 463 |
|
|
2021
Q3 | $107M | Buy |
1,535,619
+668,011
| +77% | +$46.9M | 0.03% | 510 |
|
|
2021
Q2 | $59.7M | Sell |
867,608
-460,418
| -35% | -$30.7M | 0.02% | 752 |
|
|
2021
Q1 | $85.8M | Buy |
1,328,026
+264,626
| +25% | +$17.1M | 0.03% | 578 |
|
|
2020
Q4 | $62M | Buy |
1,063,400
+270,100
| +34% | +$16.3M | 0.02% | 685 |
|
|
2020
Q3 | $50.1M | Sell |
793,300
-34,100
| -4% | -$2.36M | 0.02% | 652 |
|
|
2020
Q2 | $63.7M | Sell |
827,400
-395,200
| -32% | -$30.3M | 0.03% | 512 |
|
|
2020
Q1 | $91.4M | Buy |
1,222,600
+423,300
| +53% | +$29.2M | 0.04% | 371 |
|
|
2019
Q4 | $51.9M | Buy |
799,300
+33,500
| +4% | +$2.18M | 0.02% | 763 |
|
|
2019
Q3 | $48.5M | Buy |
765,800
+179,000
| +31% | +$11.7M | 0.02% | 706 |
|
|
2019
Q2 | $39.6M | Sell |
586,800
-118,000
| -17% | -$7.76M | 0.02% | 783 |
|
|
2019
Q1 | $45.8M | Sell |
704,800
-719,700
| -51% | -$47.8M | 0.02% | 680 |
|
|
2018
Q4 | $89.1M | Sell |
1,424,500
-723,300
| -34% | -$50.6M | 0.04% | 404 |
|
|
2018
Q3 | $166M | Sell |
2,147,800
-180,300
| -8% | -$13.6M | 0.07% | 275 |
|
|
2018
Q2 | $165M | Buy |
2,328,100
+558,200
| +32% | +$39.4M | 0.07% | 269 |
|
|
2018
Q1 | $133M | Sell |
1,769,900
-219,900
| -11% | -$17.5M | 0.06% | 307 |
|
|
2017
Q4 | $143M | Buy |
1,989,800
+205,600
| +12% | +$15.6M | 0.06% | 310 |
|
|
2017
Q3 | $145M | Buy |
1,784,200
+211,700
| +13% | +$16.2M | 0.07% | 286 |
|
|
2017
Q2 | $111M | Sell |
1,572,500
-223,600
| -12% | -$14.9M | 0.06% | 342 |
|
|
2017
Q1 | $122M | Buy |
1,796,100
+1,096,800
| +157% | +$77.1M | 0.07% | 284 |
|
|
2016
Q4 | $50.1M | Sell |
699,300
-27,600
| -4% | -$2.05M | 0.03% | 543 |
|
|
2016
Q3 | $57.5M | Buy |
726,900
+35,500
| +5% | +$2.88M | 0.03% | 471 |
|
|
2016
Q2 | $57.7M | Buy |
691,400
+17,801
| +3% | +$1.58M | 0.04% | 444 |
|
|
2016
Q1 | $61.9M | Sell |
673,599
-248,601
| -27% | -$22.4M | 0.04% | 401 |
|
|
2015
Q4 | $93.3M | Buy |
922,200
+179,700
| +24% | +$18.7M | 0.06% | 323 |
|
|
2015
Q3 | $72.9M | Buy |
742,500
+37,000
| +5% | +$4.11M | 0.05% | 352 |
|
|
2015
Q2 | $82.6M | Sell |
705,500
-460,600
| -39% | -$50.3M | 0.05% | 357 |
|
|
2015
Q1 | $114M | Sell |
1,166,100
-17,629
| -1% | -$1.79M | 0.08% | 271 |
|
|
2014
Q4 | $112M | Buy |
+1,183,729
| New | +$122M | 0.08% | 265 |
|
Other funds holding GILD
VCM
VPM
UBS Group's GILD Position: Q1 2026 in Review
UBS Group reduced its Gilead Sciences (GILD) stake by 18% in Q1 2026, selling an estimated $119M and leaving 3,930,216 shares worth $548M. The position accounts for 0.08% of the portfolio, ranked #248.
UBS Group first reported a position in GILD in Q4 2014 and has held it in 46 quarters since. The position peaked at $744M in Q2 2015. 2,310 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- UBS Group held 3,930,216 shares of Gilead Sciences worth $548M as of Q1 2026.
- UBS Group sold 849,463 Gilead Sciences shares in Q1 2026, an estimated $119M.
- Gilead Sciences made up 0.08% of UBS Group's portfolio in Q1 2026, its #248 holding.
- UBS Group first reported a position in Gilead Sciences in Q4 2014 and has held it in 46 quarters since.
- UBS Group's Gilead Sciences position peaked at $744M in Q2 2015.
- 2,310 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.